Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 20, 2026.
Filed with NSE · ISIN INE044A01028 · · 7 pages · English
Summary by 6ix AI
Sun Pharmaceutical Industries Limited has submitted a press release regarding the designation of UNLOXCYT® for a specific cancer treatment. This designation reflects the growing clinical evidence supporting UNLOXCYT® as a treatment option for this patient population. The filing serves to inform the exchange and stakeholders about this significant update in treatment guidelines.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Sun Pharmaceutical Industries' latest callSun Pharmaceutical Industries (NSE:SUNPHARMA) Q1 2027 Earnings Call · Replay · Jul 31Read the transcript of Sun Pharmaceutical Industries (NSE:SUNPHARMA) Q1 2027 Earnings CallSun Pharmaceutical Industries Limited on 6ix
Story so far
Earlier from Sun Pharmaceutical Industries
- Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
- New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
- LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU
- Sun Pharmaceutical Industries Limited Press Release Sep 28 2026
- Sun Pharma Launches (C)Taro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System
Later from Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 23, 2026.
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 30, 2026, titled "ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis".
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries